Evidence map›Paper›PMID 33312363›Full record

ArticleAmerican journal of translational research2020

RCE1 deficiency enhances invasion via the promotion of epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma.

Mengxian Tu, Xinyi Wang, Peng Chen, Jinying Li, Xiaojun Luo, Lu He, Wei Huang, Jian Hong, Chen Qu

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mengxian TuDepartment of Pathophysiology, School of Medicine, Jinan University Guangzhou 510630, Guangdong, China.
Xinyi WangDepartment of Abdominal Surgery, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University Guangzhou 510315, Guangdong, China.
Peng ChenDepartment of Abdominal Surgery, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University Guangzhou 510315, Guangdong, China.
Jinying LiDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University Guangzhou 510630, Guangdong, China.
Xiaojun LuoDepartment of Abdominal Surgery, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University Guangzhou 510315, Guangdong, China.
Lu HeGuangzhou Medical University Affiliated Cancer Hospital Guangzhou 510315, Guangdong, China.
Wei HuangDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University Guangzhou 510630, Guangdong, China.
Jian HongDepartment of Pathophysiology, School of Medicine, Jinan University Guangzhou 510630, Guangdong, China.
Chen QuDepartment of Pathophysiology, School of Medicine, Jinan University Guangzhou 510630, Guangdong, China.
Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ras converting CAAX endopeptidase 1 (RCE1) is an integral membrane protease involved in cell proliferation, differentiation, and carcinogenesis. RCE1 plays opposite roles in different tumor types; however, the actual biological function of RCE1 in hepatocellular carcinoma (HCC) is unknown. Here, we aim to investigate the prognostic value and molecular function of RCE1 in HCC. We performed immunohistochemistry in 20 normal human liver, 216 HCC, and 216 adjacent non-tumorous tissues and analyzed the expression change and clinical value of RCE1. Additionally,

Indexed as

epithelial-mesenchymal transitionHepatocellular carcinomaprognosisRCE1tumor suppressor

Identifiers

PMID33312363
PMCPMC7724357
OpenAlexW3114694545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.